These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39282050)

  • 1. Rapid genotyping of inversion variants in Mucopolysaccharidosis type II using long-range PCR: A case report.
    Hattori Y; Kido J; Sugawara K; Sawada T; Matsumoto S; Nakamura K
    Mol Genet Metab Rep; 2024 Dec; 41():101139. PubMed ID: 39282050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of a new mutation (1343-TT) in the iduronate-2-sulfatase gene from a Chinese patient with mucopolysaccharidosis type II].
    Guo YB; Du CS
    Zhonghua Er Ke Za Zhi; 2006 Feb; 44(2):110-3. PubMed ID: 16624026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type II.
    Johnson BA; van Diggelen OP; Dajnoki A; Bodamer OA
    Curr Protoc Hum Genet; 2013 Oct; 79():17.14.1-17.14.9. PubMed ID: 24510650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan.
    Hattori Y; Sawada T; Kido J; Sugawara K; Yoshida S; Matsumoto S; Inoue T; Hirose S; Nakamura K
    Mol Genet Metab Rep; 2023 Dec; 37():101003. PubMed ID: 38053932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.
    Kosuga M; Mashima R; Hirakiyama A; Fuji N; Kumagai T; Seo JH; Nikaido M; Saito S; Ohno K; Sakuraba H; Okuyama T
    Mol Genet Metab; 2016 Jul; 118(3):190-197. PubMed ID: 27246110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
    Maccari F; Rigon L; Mantovani V; Galeotti F; Salvalaio M; D'Avanzo F; Zanetti A; Capitani F; Gabrielli O; Tomanin R; Volpi N
    J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan.
    Lin HY; Chang YH; Lee CL; Tu YR; Lo YT; Hung PW; Niu DM; Liu MY; Liu HY; Chen HJ; Kao SM; Wang LY; Ho HJ; Chuang CK; Lin SP
    J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cDNA analysis disclosed the discordance of genotype-phenotype correlation in a patient with attenuated MPS II and a 76-base deletion in the gene for iduronate-2-sulfatase.
    Fukuhara Y; Miura A; Yamazaki N; So T; Kosuga M; Yanagi K; Kaname T; Yamagata T; Sakuraba H; Okuyama T
    Mol Genet Metab Rep; 2020 Dec; 25():100692. PubMed ID: 33335838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidosis type II: identification of 30 novel mutations among Latin American patients.
    Brusius-Facchin AC; Schwartz IV; Zimmer C; Ribeiro MG; Acosta AX; Horovitz D; Monlleó IL; Fontes MI; Fett-Conte A; Sobrinho RP; Duarte AR; Boy R; Mabe P; Ascurra M; de Michelena M; Tylee KL; Besley GT; Garreton MC; Giugliani R; Leistner-Segal S
    Mol Genet Metab; 2014 Feb; 111(2):133-8. PubMed ID: 24125893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence of the human iduronate 2-sulfatase (IDS) gene.
    Wilson PJ; Meaney CA; Hopwood JJ; Morris CP
    Genomics; 1993 Sep; 17(3):773-5. PubMed ID: 8244397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational spectrum of the iduronate-2-sulfatase gene in Mexican patients with Hunter syndrome.
    Ramírez-Hernández MA; Figuera LE; Rizo-de la Torre LC; Mendoza-Ruvalcaba MTMSC; Arnaud-López L; García-Ortiz JE; Zúñiga-González GM; Puebla-Pérez AM; Gómez-Meda BC; Gallegos-Arreola MP
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5115-5127. PubMed ID: 35916809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.
    Chuang CK; Lin HY; Wang TJ; Huang YH; Chan MJ; Liao HC; Lo YT; Wang LY; Tu RY; Fang YY; Chen TL; Ho HC; Chiang CC; Lin SP
    Orphanet J Rare Dis; 2018 May; 13(1):84. PubMed ID: 29801497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
    Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
    Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional assessment of the genetic findings indicating mucopolysaccharidosis type II in the prenatal setting.
    Fuller M; Ketteridge D
    JIMD Rep; 2021 Jul; 60(1):10-14. PubMed ID: 34258136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive and adaptive behaviors associated with disease severity and genotype in patients with mucopolysaccharidosis II.
    Yee KS; Alexanderian D; Merberg D; Natarajan M; Wang S; Wu Y; Whiteman DAH
    Mol Genet Metab; 2023 Nov; 140(3):107652. PubMed ID: 37506513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
    Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
    Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.